Long COVID Research Is In Its ‘ Most Hopeful ’ Phase Yet
A phenomenal amount of research on Long COVID—the name for chronic symptoms following a case of COVID-19—has been published over the past three years. But scientific advances have yet to bring relief to people who are already sick, a group estimated to include about 5% of U.S. adults but hard to precisely quantify due to the difficulty of diagnosing people correctly.
Researchers are optimistic that breakthroughs are coming. The U.S. National Institutes of Health (NIH) has launched multiple clinical trials focused on potential therapies, and several recent studies have pointed to biomarkers that may help doct...
Source: TIME: Health - October 23, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Microdosing Unveiled: Expert's Take On The Practice's Ups & Downs
Paul Austin, the trainer of psychedelics microdosing practitioners, spoke to Benzinga about his collaboration with Lauren Mugglebee, who transitioned from a career at Meta META to coaching high-end tech and corporate clients in Silicon Valley. Austin is focused on passing on knowledge and…#paulaustin #laurenmugglebee #metameta #siliconvalley #prozac #lexapro #austin #pixabay #pexels (Source: Reuters: Health)
Source: Reuters: Health - September 24, 2023 Category: Consumer Health News Source Type: news
Prolonged Antidepressant Treatment No Benefit in Bipolar I Disorder
THURSDAY, Aug. 3, 2023 -- For patients with bipolar I disorder who had recently had remission of a depressive episode, adjunctive treatment with escitalopram or bupropion XL that continues for 52 weeks does not show a significant benefit compared... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 3, 2023 Category: Pharmaceuticals Source Type: news
Mindfulness - Based Stress Reduction Safe, Effective for Anxiety Disorders
In randomized study, mindfulness - based stress reduction is noninferior to escitalopram (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 11, 2022 Category: Psychiatry Tags: Family Medicine, Internal Medicine, Pharmacy, Psychiatry, Journal, Source Type: news
Mindfulness meditation is as effective as LEXAPRO at alleviating anxiety, study finds
Researchers in Washington DC found people who meditated every day and did yoga once a week saw their anxious thoughts and feelings ease by almost a third after six weeks. (Source: the Mail online | Health)
Source: the Mail online | Health - November 10, 2022 Category: Consumer Health News Source Type: news
Mindfulness Worked as Well as an Anxiety Drug in a New Study
Mindfulness meditation worked as well as a standard drug for treating anxiety in the first head-to-head comparison.
The study tested a widely used mindfulness program that includes 2 1/2 hours of classes weekly and 45 minutes of daily practice at home. Participants were randomly assigned to the program or daily use of a generic drug sold under the brand name Lexapro for depression and anxiety.
After two months, anxiety as measured on a severity scale declined by about 30% in both groups and continued to decrease during the following four months.
Study results, published Wednesday in the journal JAMA Psychiatry, are timely....
Source: TIME: Health - November 9, 2022 Category: Consumer Health News Authors: Lindsey Tanner/AP Tags: Uncategorized healthscienceclimate Mental Health wire Source Type: news
To calm anxiety, researchers find meditation as effective as Lexapro : Shots - Health News
#lexapro #shotshealthnews (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2022 Category: Consumer Health News Source Type: news
Mindfulness-Based Stress Reduction Is As Effective As Antidepressants For Anxiety Disorders, Study Finds
Results show meditation reduced anxiety as much as the common antidepressant drug escitalopram. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 9, 2022 Category: Pharmaceuticals Authors: Ty Roush, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news Source Type: news
escitalopram
Title: escitalopramCategory: MedicationsCreated: 3/16/2003 12:00:00 AMLast Editorial Review: 8/20/2022 12:00:00 AM (Source: MedicineNet Depression General)
Source: MedicineNet Depression General - August 20, 2022 Category: Psychiatry Source Type: news
Antidepressant, Exercise Help Combat Anxiety in CHD Antidepressant, Exercise Help Combat Anxiety in CHD
Both escitalopram and exercise may help lower anxiety in adults with coronary heart disease (CHD) and high levels of anxiety ― but escitalopram has the greater impact, new research suggests.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 27, 2021 Category: Internal Medicine Tags: Psychiatry News Source Type: news
The 10 Most Important Health Breakthroughs You Missed During the Pandemic
While most eyes were on COVID-19, researchers have also made groundbreaking advancements in other fields. Here’s a look.
The other big vaccine news
Public-health officials have long sought a vaccine against malaria, which infects up to 600 million people a year and kills 400,000, mostly children. This year, there was dramatic progress toward that goal. In a study of 450 children in Burkina Faso, published in the Lancet in April, researchers reported that a new malaria vaccine, called R21, is 77% effective—just clearing the World Health Organization’s 75% efficacy standard.
However, the sa...
Source: TIME: Health - June 10, 2021 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 feature Innovation Magazine Source Type: news
The Psychedelic Drug Trial review – a mind-bending magic mushroom mission
Helmed by Prof David Nutt, this documentary follows volunteers as they swap antidepressants for psilocybin ... and it ’s the closest they’ve come to joy in yearsIn 2008, Prof David Nutt was made chair of the government ’s Advisory Council on the Misuse of Drugs. A year later, Nutt, a neuropsychopharmacologist, was sacked by the same government after insisting – I paraphrase minimally – that fags and booze were more dangerous than cannabis and ecstasy. Twelve years on, he is still clearly furious about it – not the sacking, but the lack of evidence-based thinking behind it. “I just couldn’t bear to mislead t...
Source: Guardian Unlimited Science - May 19, 2021 Category: Science Authors: Lucy Mangan Tags: Television & radio Culture Science Drugs Society Psychology Pharmacy and pharmacology Source Type: news
Author Q & A: New generation antidepressants for depression in children and adolescents
In this author interview we find out more about this recently published Network Meta-analysis,New generation antidepressants for depression in children and adolescents. Authors Dr. Sarah Hetrick and Nick Meader tell us about this work.What were you trying to find out with this Network Meta-Analysis?We were trying to find out how well newer generation antidepressants work compared with placebo and if some are more effective than others. We wanted to know how these antidepressants affect:symptoms of depression;recovery: no longer meeting diagnostic criteria for major depressive disorder;response or remission: scores on a sca...
Source: Cochrane News and Events - May 11, 2021 Category: Information Technology Authors: Rachel Klabunde Source Type: news
Psilocybin Compared With Escitalopram for Depression
No difference seen in change in depression scores at six weeks for psilocybin plus placebo versus psilocybin plus escitalopram (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - April 15, 2021 Category: Psychiatry Tags: Pharmacy, Psychiatry, Journal, Source Type: news
Psilocybin Compared With Escitalopram for Depression
THURSDAY, April 15, 2021 -- For patients with major depressive disorder, the change in scores for depression at six weeks does not differ significantly with psilocybin or psilocybin plus escitalopram, according to a study published in the April 15... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 15, 2021 Category: Pharmaceuticals Source Type: news
